One of the most common myths is that stem cells are a zero sum game. What’s a zero sum game? It’s a dynamic where the overall good in a given situation or system stays the same. What this means is that in a zero sum game, if something is good for one person, it must […]
The myth of stem cells as a zero sum game Read More »
One of my favorite stem cell scientists is Jeanne Loring of Scripps. She does great science and when you ask her questions, she frankly states her opinions and is clearly a gifted educator at heart too. Below is a Q&A interview I did with Jeanne on key issues of clinical translation of iPS cells. You
Jeanne Loring interview: optimism on clinical translation of IPS cells Read More »
If you are wondering, “How will iPS cells get to help patients?” part of the answer is perhaps the big player and Japanese Institution, Riken and its arm Retina Institute of Japan. The stem cell field is still abuzz about induced pluripotent stem (iPS) cells 7 years after their discovery. This amazing embryonic stem cell-like cells can
Meet Retina Institute of Japan: translating iPS cells Read More »
Dr. Steven Victor, CEO of Intellicell, seems to have made two comments on a recent blog post I did on stem cell sports medicine (see below). Victor and Intellicell received a warning letter from the FDA in March 2012 with the FDA. I’m not aware of Intellicell publicly addressing the FDA issues. If you have, Intellicell, please
Dr. Steven Victor of Intellicell Comments on its Stem Cell Treatments Read More »
The Harvard Stem Cell Institute yesterday posted on Facebook that they will make the biggest announcement in their history tomorrow. Big hat tip to Mohammed Mostajo for the heads up and pic on this one. Thanks! What’s that all about? I’ve been working on my sources! Possible predictions…. A. SCNT-production of genetically normal human embryonic stem cells
In my series eight simple reasons to pause before getting an unlicensed stem cell treatment from a non-compliant clinic I have covered the first five: (1) potential loss of insurance coverage for negative outcomes that could cost hundreds of thousands of dollars, (2) failure of patient follow up by the doctors and clinics, (3) exclusion from future clinical trial
How do we evaluate a stem cell journal? There is no doubt about it. The stem cell field has captured the imagination of people around the world of all occupations. Scientists themselves are captivated by stem cells. The number of articles on stem cells and the number of journals focused on stem cells are going
Stem cell journal impact factors: how does your favorite stack up? Read More »
A relatively newly recognized, important player in the stem cell field is a molecule called histone H3.3. Histones are key components of chromatin with integral roles in regulating almost all aspects of cell behavior through orchestrating functions such as transcription and chromosome segregation. Histone H3.3 knockout My lab has just (April 9) published new studies
Histone H3.3: giving cells epigenetic flexibility Read More »
Below, guest blogger, John Carbona gives us his account (including pictures) of Day 2 of the Vatican Stem Cell Meeting, which included a talk by Nobel Laureate John Gurdon. Note, you can read John’s post on Day 1 of the meeting including more great pictures here. Friday, April 12, 2012 The Second International Vatican Adult
John Carbona on Day 2 of Vatican Stem Cell Meeting including Gurdon Talk Read More »
I’ve been fortunate to interview some of the greats in the stem cell field for this blog and host debates between key players. Please note that just because I have interviewed folks does not mean I agree with them or that they agree with me. The point is to establish dialogue on key issues. As
Interviews with leaders and top players in the stem cell field Read More »